Literature DB >> 17128211

The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis.

Daniel W Nebert1, Timothy P Dalton.   

Abstract

Some cytochrome P450 (CYP) heme-thiolate enzymes participate in the detoxication and, paradoxically, the formation of reactive intermediates of thousands of chemicals that can damage DNA, as well as lipids and proteins. CYP expression can also affect the production of molecules derived from arachidonic acid, and alters various downstream signal-transduction pathways. Such changes can be precursors to malignancy. Recent studies in mice have changed our perceptions about the function of CYP1 enzymes. We suggest a two-tiered system to predict an overall inter-individual risk of tumorigenesis based on DNA variants in certain 'early defence' CYP genes, combined with polymorphisms in various downstream target genes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17128211     DOI: 10.1038/nrc2015

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  130 in total

Review 1.  Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future.

Authors:  Magnus Ingelman-Sundberg
Journal:  Trends Pharmacol Sci       Date:  2004-04       Impact factor: 14.819

Review 2.  Effects of dietary constituents on the metabolism of chemical carcinogens.

Authors:  L W Wattenberg
Journal:  Cancer Res       Date:  1975-11       Impact factor: 12.701

Review 3.  Cytochrome P450: evolution and functional diversity.

Authors:  D W Nebert; R A McKinnon
Journal:  Prog Liver Dis       Date:  1994

4.  Reductive activation of Cr(Vi) by nitric oxide synthase.

Authors:  Ryan Porter; Marie Jáchymová; Pavel Martásek; B Kalyanaraman; Jeannette Vásquez-Vivar
Journal:  Chem Res Toxicol       Date:  2005-05       Impact factor: 3.739

5.  Liver deformation in Ahr-null mice: evidence for aberrant hepatic perfusion in early development.

Authors:  Eric B Harstad; Christopher A Guite; Tami L Thomae; Christopher A Bradfield
Journal:  Mol Pharmacol       Date:  2006-01-27       Impact factor: 4.436

Review 6.  Hepatic uptake of chylomicron remnants.

Authors:  A D Cooper
Journal:  J Lipid Res       Date:  1997-11       Impact factor: 5.922

Review 7.  CAR, the continuously advancing receptor, in drug metabolism and disease.

Authors:  M Qatanani; D D Moore
Journal:  Curr Drug Metab       Date:  2005-08       Impact factor: 3.731

8.  Role of polymorphic human cytochrome P450 enzymes in estrone oxidation.

Authors:  Alastair E Cribb; M Joy Knight; Dagny Dryer; Judy Guernsey; Kimberly Hender; Marvin Tesch; Tarek M Saleh
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-03       Impact factor: 4.254

9.  Glutathione-dependent reduction of arsenate in human erythrocytes--a process independent of purine nucleoside phosphorylase.

Authors:  Balázs Németi; Zoltán Gregus
Journal:  Toxicol Sci       Date:  2004-10-06       Impact factor: 4.849

Review 10.  Cytochrome P450 pharmacogenetics and cancer.

Authors:  C Rodriguez-Antona; M Ingelman-Sundberg
Journal:  Oncogene       Date:  2006-03-13       Impact factor: 9.867

View more
  272 in total

1.  Methodological approaches to cytochrome P450 profiling in embryos.

Authors:  Jared V Goldstone; John J Stegeman
Journal:  Methods Mol Biol       Date:  2012

2.  Molecular characterization of the Camelus dromedarius putative cytochrome P450s genes.

Authors:  Mohammad Saud Alanazi; Hesham Mahmoud Saeed; Farid Shokry Ataya; Mohammad Dawoud Bazzi
Journal:  Protein J       Date:  2010-07       Impact factor: 2.371

3.  Genetic variants in carcinogen-metabolizing enzymes, cigarette smoking and pancreatic cancer risk.

Authors:  Ji-Hyun Jang; Michelle Cotterchio; Ayelet Borgida; Steven Gallinger; Sean P Cleary
Journal:  Carcinogenesis       Date:  2012-02-02       Impact factor: 4.944

4.  Xenobiotic metabolizing genes, meat-related exposures, and risk of advanced colorectal adenoma.

Authors:  Leah M Ferrucci; Amanda J Cross; Marc J Gunter; Jiyoung Ahn; Susan T Mayne; Xiaomei Ma; Stephen J Chanock; Meredith Yeager; Barry I Graubard; Sonja I Berndt; Wen-Yi Huang; Richard B Hayes; Rashmi Sinha
Journal:  World Rev Nutr Diet       Date:  2010-04-30       Impact factor: 0.575

5.  Tobacco carcinogen-metabolizing genes CYP1A1, GSTM1, and GSTT1 polymorphisms and their interaction with tobacco exposure influence the risk of head and neck cancer in Northeast Indian population.

Authors:  Javed Hussain Choudhury; Seram Anil Singh; Sharbadeb Kundu; Biswadeep Choudhury; Fazlur R Talukdar; Shilpee Srivasta; Ruhina S Laskar; Bishal Dhar; Raima Das; Shaheen Laskar; Manish Kumar; Wetetsho Kapfo; Rosy Mondal; Sankar Kumar Ghosh
Journal:  Tumour Biol       Date:  2015-02-28

Review 6.  EET signaling in cancer.

Authors:  Dipak Panigrahy; Emily R Greene; Ambra Pozzi; Dao Wen Wang; Darryl C Zeldin
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

7.  Ligand-independent activation of aryl hydrocarbon receptor signaling in PCB3-quinone treated HaCaT human keratinocytes.

Authors:  Wusheng Xiao; Jyungmean Son; Sabine U Vorrink; Frederick E Domann; Prabhat C Goswami
Journal:  Toxicol Lett       Date:  2015-02-07       Impact factor: 4.372

8.  Basal and inducible CYP1 mRNA quantitation and protein localization throughout the mouse gastrointestinal tract.

Authors:  Shigeyuki Uno; Nadine Dragin; Marian L Miller; Timothy P Dalton; Frank J Gonzalez; Daniel W Nebert
Journal:  Free Radic Biol Med       Date:  2007-11-12       Impact factor: 7.376

9.  CYP3A5*3 polymorphism and cancer risk: a meta-analysis and meta-regression.

Authors:  Bao-Sheng Wang; Zhen Liu; Wei-Xue Xu; Shao-Long Sun
Journal:  Tumour Biol       Date:  2013-04-13

10.  Generation of a 'humanized' hCYP1A1_1A2_Cyp1a1/1a2(-/-)_Ahrd mouse line harboring the poor-affinity aryl hydrocarbon receptor.

Authors:  Zhanquan Shi; Ying Chen; Hongbin Dong; Robyn M Amos-Kroohs; Daniel W Nebert
Journal:  Biochem Biophys Res Commun       Date:  2008-09-22       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.